Eur Respir J 1998; 11: 1098-1104
Copyright © ERS Journals Ltd 1998
Platelet-activating factor increases leukotriene B4 release in stimulated alveolar macrophages from asthmatic patients
K Shindo,
K Koide,
and
M Fukumura
This study was designed to examine further the role of platelet-activating factor (PAF) in asthma, comparing leukotriene B4 (LTB4) release, 5-lipoxygenase activity and intracellular calcium levels ([Ca2+]i) in macrophages. LTB4 and other lipoxygenase metabolites in macrophages in bronchoalveolar lavage fluids obtained from 23 asthmatic patients and 20 control subjects were measured by reverse-phase high-performance liquid chromatography. [Ca2+]i was monitored using the fluorescent probe fura-2. The basal LTB4 release of resting macrophages was not different between groups (0.02+/-0.01 versus 0.05+/-0.02 ng x 10(-6) cells). When stimulated with calcium ionophore A23187 (2.5 microM), however, macrophages from asthmatic patients released more LTB4 than cells from control subjects (30.2+/-3.4 versus 13.7+/-2.1 ng x 10(-6) cells). Although PAF alone did not alter LTB4 release, it enhanced the response to subsequent A23187 stimulation. This effect was noted following short treatment (i.e., 5 min) at concentrations of > or =1.0 microM PAF, with the maximal effect noted after treatment with 5.0 microM PAF + 2.5 microM A23187 (105.1+/-6.7 versus 15.3+/-2.6 ng x 10(-6) cells). Treatment of macrophages with PAF also increased 5-lipoxygenase activity and [Ca2+]i more in cytosols from asthmatic patients than in cytosols from control subjects. These findings support a role of intracellular calcium in the activation of 5-lipoxygenase which, in turn, augments the release of leukotriene B4. Because levels of platelet-activating factor may be increased in the lung during asthma and can increase the subsequent release of a chemotactic mediator leukotriene B4, from macrophages, these findings suggest that platelet-activating factor may prime the constitutive cells of the lung to augment inflammatory effects important in the pathogenesis of asthma.
This article has been cited by other articles:

|
 |

|
 |
 
T. K. Finney-Hayward, P. Bahra, S. Li, C. T. Poll, A. G. Nicholson, R. E. K. Russell, P. A. Ford, J. Westwick, P. S. Fenwick, P. J. Barnes, et al.
Leukotriene B4 release by human lung macrophages via receptor- not voltage-operated Ca2+ channels
Eur. Respir. J.,
May 1, 2009;
33(5):
1105 - 1112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Barnes
Mediators of Chronic Obstructive Pulmonary Disease
Pharmacol. Rev.,
December 1, 2004;
56(4):
515 - 548.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Gabrijelcic, A. Casas, R.A. Rabinovich, J. Roca, J.A. Barbera, K.F. Chung, and R. Rodriguez-Roisin
Formoterol protects against platelet-activating factor-induced effects in asthma
Eur. Respir. J.,
January 1, 2004;
23(1):
71 - 75.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Gabrijelcic, A. Acuna, M. Profita, A. Paterno, K.F. Chung, A.M. Vignola, and R. Rodriguez-Roisin
Neutrophil airway influx by platelet-activating factor in asthma: role of adhesion molecules and LTB4 expression
Eur. Respir. J.,
August 1, 2003;
22(2):
290 - 297.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the European Respiratory Society.
|